

1 **Colonization of intervertebral discs by *Cutibacterium*** 2 ***acnes* in patients with low back pain: protocol for an** 3 **analytical study with microbiological, phenotypic,** 4 **genotypic, and multiomic techniques**

5 Vinícius Magno da Rocha¹, Carla Ormundo Gonçalves Ximenes Lima², Eliane de
6 Oliveira Ferreira²; Gabriel Corrêa de Farias³; Fábio César Sousa Nogueira⁴; Luis
7 Caetano Martha Antunes⁵; Keila Mara Cassiano⁶; Rossano Kepler Alvim Fiorelli¹

8 ¹Departamento de Cirurgia geral e especializada, Escola de Medicina, Universidade
9 Federal do Estado do Rio de Janeiro (UniRio), Rio de Janeiro- RJ, Brazil; ²
10 Departamento de Microbiologia Médica, Instituto de Microbiologia Paulo de Góes,
11 Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro-RJ, Brazil;
12 ³Departamento de Biologia Celular e Molecular, Fundação Oswaldo Cruz, Rio de
13 Janeiro – RJ, Brazil; ⁴Instituto de Química, Universidade Federal do Rio de Janeiro
14 (UFRJ), Rio de Janeiro-RJ, Brazil; ⁵Centro de Desenvolvimento Tecnológico em
15 Saúde, Fundação Oswaldo Cruz, Rio de Janeiro – RJ, Brazil; ⁶Departamento de
16 Estatística, Instituto de Matemática, Universidade Federal Fluminense (UFF), Niterói-
17 RJ, Brazil;

18 **Corresponding author:** Eliane de Oliveira Ferreira, Av. Carlos Chagas Filho, 373,
19 CCS, Bloco I, 2 andar, Laboratório de Biologia de Anaeróbios, Departamento de
20 Microbiologia Médica, UFRJ, Rio de Janeiro-RJ, Brasil. E-mail:
21 eliane_ferreirarj@micro.ufrj.br

22 **Keywords:** Intervertebral discs; *Cutibacterium acnes*; low back pain; analytical study;
23 multiomic techniques.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

24 **Abstract**

25

26 Lumbar disc degeneration (LDD) and low back pain (LBP) are two conditions that are
27 closely related. Several studies have shown *Cutibacterium acnes* colonization of
28 degenerated discs, but whether and how these finding correlates with LBP is unknown.
29 A prospective study was planned to identify molecules present in lumbar intervertebral
30 discs (LLIVD) colonized by *C. acnes* in patients with LDD and LBP and correlate them
31 with their clinical, radiological, and demographic profiles. The clinical manifestations,
32 risk factors, and demographic characteristics of participants undergoing surgical
33 microdiscectomy will be tracked. Samples will be isolated and pathogens found in
34 LLIVD will be characterized phenotypically and genotypically. Whole genome
35 sequencing (WGS) of isolated species will be used to phylotype and detect genes
36 associated with virulence, resistance, and oxidative stress. Multiomic analyses of
37 LLIVD colonized and non-colonized will be carried out to explain not only the
38 pathogen's role in LDD, but also its involvement in the pathophysiology of LBP. This
39 study was approved by the Institutional Review Board (CAAE
40 50077521.0.0000.5258). All patients who agree to participate in the study will sign an
41 informed consent form. Regardless of the study's findings, the results will be published
42 in a peer-reviewed medical journal. Trials registration number NCT05090553; pre-
43 results.

44 Introduction

45 LBP is a common complaint in the general population, and its incidence is about five
46 times higher in patients with LDD and Modic endplate changes.(1,2) The link between
47 these findings and the isolation of low virulence pathogens in LIVD has already been
48 described in several studies, generating a lot of interest in the topic and promoting the
49 bacterial hypothesis of LDD.(3–14)

50 Albert et al. reported 46% of positive cultures for anaerobes in 61 patients undergoing
51 lumbar discectomy, of which 80% had Modic type 1 changes.(15) Other studies
52 corroborate these findings, with high identification rates for *Cutibacterium acnes*, an
53 anaerobic and aerotolerant pathogen that is bacillus-shaped, stained by the Gram
54 method, pleomorphic, non-spore-forming, and a biofilm producer.(11,16–20) Rollason
55 et al. isolated strains of this bacterium from the LIVD of 64 patients, revealing the
56 presence of genotypic profiles distinct from those found in the skin, suggesting that
57 specific variants would be related to LBP.(21)

58 Other authors believe that the presence of this pathogen in the LIVD of asymptomatic
59 patients is due to contamination of the specimens during sampling and/or sample
60 treatment in the laboratory environment. Carricajo et al. found positive cultures for *C.*
61 *acnes* in only 3.4% of the discs from 54 patients, defending the possibility of
62 contamination.(22) Rigal et al. also analyzed LIVD from 313 patients who underwent
63 video-assisted retroperitoneal discectomy, with positive cultures for only six
64 patients.(23)

65 These marked divergences in microbiological results cast doubt on the bacterial
66 hypothesis of LDD and, consequently, raise questions about the possibility of

67 anaerobic pathogens acting as triggers or amplifiers of LBP. Urquhart et al. conducted
68 a systematic review of the literature on the subject and concluded that there is
69 evidence correlating the *C. acnes* isolation with Modic type 1 changes and LBP, but
70 there is a lack of studies producing substantial and irrefutable evidence.(24)

71 Despite the fact that considerable effort has already been expended in determining
72 the presence of *C. acnes* in LIVD, there are still no standard isolation protocols for this
73 pathogen from this clinical specimen. Furthermore, prior to the preparation of this
74 manuscript, studies have shown no consistency in the collection and analysis
75 techniques used, making comparison and reproducibility of results difficult.

76 Aware of this reality, Astur et al. proposed a protocol for a cohort study to identify *C.*
77 *acnes* from intervertebral discs.(25) Although valid, the initiative has two significant
78 limitations that should be highlighted. First, after collecting clinical specimens, their
79 immediate inoculation in a liquid medium is not foreseen in the operating room, which
80 increases the contact time of the samples with the aerobic environment and reduces
81 the chances of microorganism recovery even with culture-specific techniques. Second,
82 the authors also highlight sonication (ultrasound waves to release bacteria from the
83 biofilm of surgical prostheses) of specimens for subsequent inoculation in automated
84 blood culture vials; however, this technique was originally described for pathogen
85 recovery from orthopedic prostheses rather than biological tissue(26) and, because
86 the sonication parameters used are not clear (time, power, and frequency), the
87 reproduction of results by other authors and the validation of this protocol is
88 compromised.

89 Specific microbiological identification techniques, such as immediate inoculation of
90 specimens in liquid culture medium while still in the operating room, vortex¹ for sessile
91 cell recovery, incubation time extension in an anaerobic atmosphere with replication
92 every 72 h, and the use of Matrix-Assisted Laser Desorption Ionization Time of Flight
93 Mass spectrometry - MALDI-TOF MS (Bruker Corporation), and multiplex-touchdown
94 PCR² are strategies that assure reliable results regarding the presence of bacteria in
95 intervertebral discs (27,28), but they do not explain the pathways through which these
96 microorganisms would participate in LDD and/or LBP.

97 Once LIVD colonization by *C. acnes* is confirmed using microbiological techniques, in
98 the absence of clinical signs of infection, the main challenge is to understand the
99 implications of this finding for homeostasis of that microenvironment. Rajasekaran et
100 al. showed strong evidence of LIVD colonization by *C. acnes* using rDNA-16s PCR
101 and proteomic analyses (29). These authors discovered not only host defense
102 proteins, but also proteins associated with bacterial viability and proliferation. Although
103 these findings have demonstrated the active presence of *C. acnes* in intervertebral
104 discs, definitively ruling out the possibility of contamination, they do not necessarily
105 reflect the activity of the expressed proteins, which may remain inactive and without
106 interference in pain-generating pathways and/or the inflammatory response.

107

108 In this context, the combined use of proteomic and metabolomic techniques to analyze
109 LIVD colonized by *C. acnes* would be more appropriate in order to assess the
110 subclinical consequences of the colonization by this pathogen.(30) These techniques
111 have already been used successfully to define molecular signatures in other clinical
112 settings,(31–34) especially in chronic pain,(35–40) and can also provide integrative
113 information on cell function at the molecular level about the role of *C. acnes* in LDD
114 and LBP.(41–44)

115 **Hypotheses and objectives**

116 Our hypothesis is that LDD and LBP are related to LIVD colonization by *C. acnes*.
117 The primary goal of this study is to determine the incidence of LIVD colonization by
118 low virulent pathogens using specific sampling and culture techniques, as well as
119 phenotypic and genotypic techniques for microbiological characterization.

120 Other objectives of the study include: 1- assessing the possibility of clinical specimen
121 contamination in positive cultures; 2- establishing a correlation between the presence
122 of the pathogen and the clinical and radiological profile (Modic type 1 changes) of the
123 study participants; 3- to outline a phylotypic profile of the most isolated *C. acnes* strains
124 by bacterial WGS; and 4- identify a molecular profile for LDD and LBP in patients with
125 positive cultures for *C. acnes* through proteomic and metabolomic techniques.

126 **Justifications**

127 Colonization of LIVD by *C. acnes* in patients with LDD supports the bacterial
128 hypothesis of LBP (4,8,29,45–47). The determination of a molecular profile for these
129 patients will not only contribute to a better understanding of the pathophysiological

130 basis of LBP associated with LDD (41–43), but it will also positively interfere in the
131 clinical management of this common condition, rationalizing its treatment and
132 optimizing its costs.

133 Previously studies looked at small groups of patients and did not follow standardized
134 sampling and analysis methods.(15,24,48,49) This makes it difficult to value these
135 findings and while they do suggest a correlation between *C. acnes* and LBP, the
136 evidence is insufficient to explain how this bacterium could be involved in the process
137 of LIVD degeneration and generation/amplification of LBP.

138 This is the first protocol to investigate the role of *C. acnes* in LIVD degeneration,
139 combining isolation with culture techniques, phenotypic and genotypic
140 characterization techniques; and genomic, proteomic, and metabolomic techniques.
141 In addition, the protocol proposes the clinical–radiological characterization of the
142 participants, blinding the researchers and controlling confounding variables, and
143 following appropriate selection criteria and statistical planning to obtain significant
144 results.

145 **Methods and Analysis**

146 This study protocol is registered with the Research Ethics Committee (REC) [CAAE:
147 50077521.0.0000.5258] of the Gaffrée and Guinle University Hospital (HUGG) and at
148 *Clinicaltrials.gov* under NCT05090553
149 (<https://clinicaltrials.gov/ct2/results?term=NCT05090553>).

150 **Study Design**

151 This analytical study will be performed at a single location (Spine Surgery Center of
152 São Matheus Hospital (HSM) in collaboration with the Gaffrée Guinle University
153 Hospital (HUGG) and Anaerobic Biology Laboratory of Paulo de Góes Microbiology
154 Institute of the Universidade Federal do Rio de Janeiro (UFRJ).

155 The analyses will be performed sequentially, according to the surgical procedures
156 carried out on the selected participants, taking 6 months after for their recruitment and
157 ending 6 months after the surgical treatment of the last patient. Data from participants
158 will be collected using a form designed specifically for this study.

159 **Population**

160 Participants included in the study must meet the selection criteria listed below.

161 **Inclusion Criteria**

162 The inclusion criteria for the study will be participants aged between 18 and 65 years;
163 both sexes; complaint of low back pain lasting more than 3 months; magnetic
164 resonance imaging findings of lumbar disc degeneration (LDD) performed less than 6
165 months before inclusion in the study; indication for open surgical treatment with
166 isolated microdiscectomy or associated with lumbar arthrodesis; failure of
167 conservative treatment for at least 6 weeks and/or progressive neurological deficit;
168 agreement to follow all phases of the clinical investigation, having signed the informed
169 consent form (ICF) for participation in the study.

170 **Exclusion Criteria**

171 The exclusion criteria for the study will be a history of open lumbar spine surgery at
172 any stage of life; chemotherapy or pulse therapy with corticoids; immune deficiency;
173 previous intradiscal therapies (nucleotomy or discography); previous endoscopic
174 surgery; history of spinal infection treated with antibiotics in the 6 months prior to
175 inclusion in the study; use of antibiotics in the 2 months prior to the surgical procedure;
176 incomplete research inclusion form; refusal to participate and/or sign the ICF.

177 **Patient and Public involvement**

178 Participant eligibility will be evaluated by the study researchers through a clinical
179 interview and imaging exams evaluation, according to the participants' interest and
180 availability to participate in the study. If the patient agrees to take part in the study, the
181 predetermined selection criteria will be used to evaluate them. The researchers will
182 explain the details of the study and conduct a joint reading of the ICF. Questions about
183 the study objectives, risks and benefits, stages, and research confidentiality will be
184 answered. A patient will only participate upon signing the ICF at this stage of the
185 research. A copy of this document will be given to the participant, another to the
186 responsible researcher, and a third will be attached to the medical record. After signing
187 the consent form, the patient will undergo an evaluation for demographic and clinical
188 data collection and the forms developed for this purpose will be completed. If the
189 patient is unable to read and sign the written consent form, researchers will verbally
190 explain the study details and the patient will orally provide consent in the presence of
191 a witness who will sign the consent form. The recruitment of participants will take place
192 over a 6-month period, until 120 individuals are included, aiming at a minimum number
193 of 96 collections.

194 **Participant Allocation**

195 The participants will be operated by the same surgical team, and the surgical
196 technique will be posterior discectomy followed by arthrodesis of the approached
197 segment.

198 **Blinding**

199 The results of microbiological cultures or molecular analysis will not be disclosed
200 neither to the patients nor to the surgeons. The radiologist who will review the imaging
201 tests will also be blinded to patient data and laboratory results. The researcher who
202 will be analyzing the pain and function scores will be blinded as well.

203 **Withdrawal of a Study Participant**

204 A participant will be removed from the study in cases of ICF withdrawal, death,
205 recruitment failure identification, loss of post-surgical follow-up, or the presentation of
206 clinical symptoms of infection, intense pain, fever without other infectious *foci*,
207 increased erythrocyte sedimentation rate and/or C-reactive protein, leukocytosis,
208 imaging tests compatible with spondylodiscitis, or any other condition that leads to
209 blinding interruption.

210 The reason and circumstances of each participant's withdrawal from the study will be
211 detailed. The data gathered until the patient is withdrawn from the study will be
212 included in the final analysis.

213 **Selection of Outcomes**

214 **Primary Outcome**

215 The main objective of this study will be to determine the incidence of intervertebral
216 disc colonization by *C. acnes* in patients with LBP and LDD. Positive cultures will be
217 used to confirm colonization, followed by phenotypic and genotypic confirmation of the
218 isolated pathogen by mass spectrometry (Biotyper) and rDNA-16s PCR analysis,
219 respectively.

220 **Secondary Outcomes**

221 **Low back pain**

222 At the time of patient recruitment the Visual Numeric Scale (VNS)(50) will be used to
223 assess LBP intensity and daily activity limitations. A 30% increase in baseline LBP in
224 the first postoperative month will be considered clinically significant. The VNS and the
225 visual analogue scale have a good correlation and are equally sensitive to quantifying
226 postoperative pain.(51)

227 **Quality of life**

228 The validated Portuguese version of the EuroQol questionnaire (EQ-5D) will be used
229 to assess the quality of life of colonized and non-colonized groups with and without
230 Modic changes.(52) The EQ-5D is a self-administrated standardized instrument
231 containing five items (mobility, self-care, usual activities, pain/discomfort, and
232 anxiety/depression).

233 **Functionality**

234 The functionality of the participants will be quantified through the validated Portuguese
235 version of the Oswestry Disability Index (ODI) for LBP.(53)

236

237 **Host multiomic characteristics**

238 Proteomic and metabolomic techniques will be used to examine disc and plasma
239 samples. The comparison of the group of molecules found in disc and plasma samples
240 may contribute to the quantitative and qualitative identification of profiles using
241 peripheral blood that are associated with the presence of the pathogen in the
242 intervertebral disc. After processing the multiomic raw data using proper bioinformatics
243 tools, statistical techniques will be applied to analyze them against the clinical–
244 radiological and microbiological profiles of the participants. We expect to provide a
245 molecular signature relating the presence of *C. acnes*, LDD and LBP.

246 **Adverse Effects**

247 Failures related to surgical treatment, such as surgical wound infection, CSF leak,
248 deep vein thrombosis, pain recurrence, or any other adverse events that may arise in
249 the postoperative period, will be reported and considered in data analysis.

250 **Sampling**

251 The Schedule of enrolment, Interventions, and assessments is shown in Fig. 1. During
252 anesthetic induction, intravenous antibiotic prophylaxis will be administered after
253 patient admission to the operating room. Cefazolin at a dose of 1 g replicated every 4
254 h for the duration of the surgery will be used as an antimicrobial drug. The antibiotic
255 prophylaxis regimen will end with skin closure and will not be extended for additional
256 postoperative time (Fig 2).

257 **This is the legend of Fig 2.** Flowchart showing all stages of the study.

258

259

260 The clinical specimens collected will be:

261

262 1. Peripheral blood. A 10 mL aliquot will be obtained 30 min after the infusion of
263 surgical antibiotic prophylaxis through upper limb venoclysis. This sample will be
264 placed in a tube containing clot activator for further separation of the serum, which,
265 in turn, will be stored at -80°C for further analysis.

266 2. Skin swab. After skin asepsis with 2% chlorhexidine gluconate degerming solution
267 and 0.5% chlorhexidine gluconate alcoholic solution, a swab will be collected from
268 the region where the surgical incision will be performed.

269 3. Intervertebral disc. Five fragments will be collected at each level approached
270 during surgery. A set of sterile surgical tweezers will be used exclusively for
271 collection, one for each tissue fragment collected. The forceps with tissue
272 fragment will be given to a member of the laboratory who will monitor the
273 procedure inside the operating room immediately after collection. Each fragment
274 will be placed in a vial containing thioglycolate broth (Merck®, Brazil) and 20 glass
275 beads. The vials will be labeled with the initials of the study participants and the
276 type of clinical specimen. After collection, the vials containing the clinical
277 specimens will be kept at room temperature (18°C to 22°C) and transported in a
278 specific case to the laboratory within a maximum period of 2 h.

279 4. Muscle–ligament tissue. Before obtaining the LIVD fragments, five fragments of
280 muscle–ligament tissue adjacent to the collected disc will be collected. The same
281 collection and initial cooling precautions used for the disc fragments will be
282 followed when collecting the adjacent tissue.

283 **Laboratory Analysis**

284 **Cultures**

285 The skin swabs will be opened only in a laboratory setting. Samples will be seeded on
286 blood agar plates (5% defibrinated sheep blood; blood agar base, 40 g/L; agar, 5 g/L)
287 and anaerobic blood agar (5% defibrinated sheep blood; blood agar base, 40 g/L;
288 agar, 5 g/L; hemin, 10 mL/L; menadione, 5 drops/L. After sowing in solid media, the
289 swab will be inoculated in thioglycolate medium, where it will remain for 14 days. One
290 of the plates will be incubated in a capnophilic atmosphere (5% to 10% CO₂), while
291 the other will be incubated in strict anaerobiosis (atmosphere containing 10%
292 CO₂, 10% H₂, and 80% N₂) using an anaerobic chamber or Glove Box (Coy Labs®,
293 USA).

294 The plates will be read after 24 h of incubation and, in case of growth, the colonies will
295 be identified. In the absence of growth, they will be incubated again, and a new reading
296 will be performed after 72 h. The thioglycolate vials containing skin swabs will be kept
297 in a bacteriological incubator (35°C to 37°C) for 14 days.

298 In a laboratory setting, the tubes containing disc fragments and muscle–ligament
299 tissue will undergo vortexing (Even EVX2800-BI®, Brazil) for 15 s. All tubes will be kept
300 in a bacteriological incubator (35°C to 37°C) and, after 24 h, the first subculture will be
301 carried out using a 100 µL bacteriological loop. An aliquot of the thioglycolate will be

302 taken and plated on blood agar and anaerobic blood agar. The first plate will be
303 incubated in a capnophilic atmosphere and the second in strict anaerobiosis using an
304 anaerobic chamber or Glove Box (Coy Labs®, USA). The plates will be read after 24
305 h and the colonies will be identified in case of growth. In the absence of growth, they
306 will be incubated again, and a new reading will be performed after 72 h. The same
307 procedure will be used for all thioglycolate vials (totaling six vials for each level
308 approached). Thioglycolate tubes containing the clinical specimens will be kept in an
309 oven for 14 days. Subcultures will be carried out after 72 h and always every 3 days,
310 with the last subculture being carried out on the 14th day of incubation in the same
311 solid culture medium and atmospheres used in the first 24 h.

312 **Quality control of culture media**

313 Sterile saline solution at 0.9% will be used to control the sterility of the culture medium
314 and *Pseudomonas aeruginosa* ATCC 27853 and *Bacteroides fragilis* ATCC 25285
315 strains to evaluate the recovery capacity of facultative microorganisms and strict
316 anaerobes. Each new batch of culture medium prepared will undergo this quality
317 control.

318 **Phenotypic characterization**

319 The phenotypic identification of the species will be carried out through mass
320 spectrometry using MALDI-TOF MS equipment (Bruker Biotyper®, Germany). The
321 score used for reliable identification of pathogens will follow the manufacturer's
322 instructions.

323 **Genotypic characterization**

324 The microorganisms isolated from cultures will be subjected to PCR analysis
325 performed in two phases, as described by Bernard et al. (28) The first to confirm the
326 presence of bacteria (target and non-target) by using species-specific primers
327 targeting the rRNA-16s and a second one, Multiplex_PCR, targeting the virulence and
328 oxidative gens.

329 **Multiomic Analyses**

330 **Whole Genome Sequencing**

331 For the WGS, the DNA of the isolated *C. acnes* strains will be obtained with the Qiagen
332 Blood & Tissue DNA extraction kit (Qiagen®, USA) and subsequent sample purification
333 using RNase.

334
335 The extracted and purified DNA will be dosed, and adjusted to a concentration of 0.2
336 ng/μL. The ends of its two ribbons will be fragmented and tagged (forward and reverse
337 5'--3'). This will form fragments of different sizes. This data will be used to create a
338 database on the Nextera Flex Kit platform (Illumina®, USA). The samples will then be
339 multiplexed into a cell stream and run on the NextSeq sequencer (Illumina®, USA)
340 using paired sequencing to generate files in fastq format files, which will then be filtered
341 using the Trimmomatic tool version 0.36, as recommended by Bolger et al.(54) This
342 step will be critical for controlling the quality of the analysis because it reduces the
343 possibility of errors during sequencing and allows the use of more reliable reading
344 codes.

345
346 The obtained fragments will be sequenced, and their quality will be evaluated with the
347 FastQC tool version 0.11.9. The RedDog software version 1.11 will be used to identify
348 single nucleotide polymorphisms (SNPs) using the GCA_000008345.1 *C. acnes*

349 reference strain deposited in the GenBank NCBI
350 [<https://www.ncbi.nlm.nih.gov/nucore/>] as a comparison. Finally, the PATRIC
351 software version 3.5.21 will be used to create a complete genome phylogeny from the
352 concatenation of SNPs.

353 **Proteomics**

354 In this study, proteomics approaches will apply gel-free and in-gel protein digestion by
355 using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
356 technique and (2)

357
358 Thioglycolate culture mediums will be centrifuged, and the sediment obtained will be
359 washed in phosphate buffer and centrifuged again. The sediment will be dissolved in
360 a lysis solution containing 8 M urea, 2% 3-[(3-cholamidopropyl) dimethylammonio]-1-
361 propanesulfonate, and 40 mM Tris (hydroxymethyl) aminomethane. This lysis will be
362 complemented with the use of glass beads under a Bead Beater agitation (Biospec
363 Product®, USA) (3 × 20 s with intervals of 20 s) followed by cooling for 5 min on an ice
364 bath, as described by Shah et al.(55) Protein concentration will be measured and 20
365 µg will be used for both the gel and solution techniques.

366
367 The SDS-PAGE -based technique will be used to evaluate the profile of the proteins
368 present in the extract. Proteins will be removed from the gel with a sterile scalpel,
369 eluted, and trypsinized (proteolic digestion) for further analysis through mass
370 spectrometry. In the solution technique, the obtained extract will be trypsinized for
371 further analysis through mass spectrometer. Regardless of the technique used, a
372 nano-Liquid Chromatography coupled to a high-resolution mass spectrometer (nLC-
373 HRMS) will be used.

374
375 After analysis by both techniques, the raw data (.raw) will be converted into a mascot
376 general file (.mgf) using the Mascot Distiller software version 2.8.0, and proteins will
377 be identified using protein banks referring to *C. acnes* and eukaryotes (humans), both
378 created using the NCBI as a *fasta* extension. After this identification, the data will be
379 validated using the Scaffold software version 5 for the same databases. Two biological
380 replicas will be made for both the gel and solution technique. The Interactivenn.net
381 [<http://www.interactivenn.net/index.html>](56) and STRING version 11 software (57)
382 will be used for comparative analysis and functional interaction of proteins,
383 respectively.

384 **Metabolomics**

385 The metabolomic analysis in this study will use intervertebral disc fragments with and
386 without isolated *C. acnes*. The tubes containing the disc fragments in thioglycolate
387 liquid culture medium will be centrifuged and the sediment will be transferred to 2 mL
388 flat-bottom polypropylene tubes containing a titanium bead (one per tube). The liquid
389 content of these tubes will be evaporated by centrifugation with the CentriVap
390 SpeedVac apparatus (Labconco Corporation®, USA) and then weighed to determine
391 the dry weight. The tubes will then have 500 µL of MS Grade (Fluka) acetonitrile added
392 followed by Bead Beater agitation (Biospec Product®, USA) (4 x 30 s). When all the
393 material has been dissolved, the tubes will be centrifuged, and the supernatant will be
394 stored at -80°C in new sterile tubes. To identify the metabolites, the material will be
395 injected into a high-resolution mass spectrometer (UHPLC Q-TOF MS/MS). The data
396 obtained will be analyzed in the Metaboanalyst 5.0 database
397 [<https://www.metaboanalyst.ca/>] and its functions and interactions in the STRING
398 software version 11.(57)

399 **Questionnaires**

400 Questionnaires on pain (VNS), functionality (ODI), and quality of life (EQ-5D) will be
401 given at recruitment as well as at 1, 3, and 6 months postoperatively. A professional
402 who is not involved in the study will collect all questionnaires. Follow-up clinical visits
403 will be carried out at 1, 3, and 6 months postoperatively, with acceptance deviation of
404 7, 14, and 21 days, respectively.

405 **Imaging Studies**

406 Imaging studies include 1.5 T magnetic resonance imaging. The tests must be dated
407 no later than 6 months prior to the participant's inclusion in the study. Any of the
408 following changes will be considered disc degeneration: disc protrusion, extrusion, or
409 sequestration; reduced disc intensity; annular ruptures; Schmorl's nodes (Depressions
410 on the surface of the vertebral bodies identified on MRI scans that result from the
411 pressure exerted by the intervertebral discs on the endplates, causing intervertebral
412 disc tissue herniation and displacement into the adjacent vertebral bodies); Modic
413 changes; and/or loss of disc height.

414 **Modic Changes**

415 The presence of Modic type 1 changes will be considered in the evaluation of magnetic
416 resonance images. This change is characterized by the presence of a high signal on
417 T2-weighted sequences, with reduced signal on T1-weighted sequences.(1,2) The
418 frequency of Modic type 1 changes in the participants will be calculated for each of the
419 research groups (presence or absence of colonization) and for the total number of
420 discs analyzed in the laboratory.

421

422 **Pfirschmann Classification**

423 Degenerative changes identified in the discs will be categorized according to the
424 Pfirschmann classification(58) using T2-weighted magnetic resonance images.

425 **Confounding Variables**

426 As some of this information may change during the study, the data obtained at the
427 time of inclusion in the study will be considered. Below are the confounding variables
428 to be analyzed:

- 429 ● Age
- 430 ● Sex
- 431 ● Education
- 432 ● Leave of absence
- 433 ● Alcohol consumption
 - 434 1. None or sporadically (< 1 dose/day)
 - 435 2. Mild (1–2 doses/day)
 - 436 3. Moderate/High (≥ 3 doses/day)
- 437 ● Smoking
 - 438 1. Non-smoker
 - 439 2. Smoker
 - 440 3. Ex-smoker
- 441 ● Body mass index
 - 442 1. Underweight (< 18.5 Kg/m²)
 - 443 2. Normal (18.5–25 Kg/m²)
 - 444 3. Overweight (25–30 Kg/m²)
 - 445 4. Obese (> 30 Kg/m²)
- 446 ● Physical activity practice
 - 447 1. Sedentary (not performing physical activity for at least 10 continuous
448 minutes during the week)
 - 449 2. Active (vigorous activities for three or more days/week and for 20 min or
450 more per session; or moderate activity or walking for five or more
451 days/week and for 30 min or more per session; or any activity added
452 together 5 or more days/week and 150 min or more/week)
 - 453 3. Very active (vigorous activity for five or more days/week and 30 min or
454 more per session; vigorous activity for three or more days/week and 20
455 min or more per session, more moderate activity and/or walking for five
456 or more days/week and for 30 min or more per session)

- 457 ● Use of oral steroids up to 3 months before surgery
- 458 ● Diabetes

459 **Statistical planning**

460 **Sample size calculation**

461 Considering the main outcome proposed, the identification of disc colonization by *C.*
462 *acnes*, the minimum sample size (n) for the population of interest will be 96
463 participants, according to the calculation described by Medronho et al.,(59) using a
464 confidence interval of 95% and a maximum margin of error of 10%.

465 The ideal sample size for analysis of secondary outcomes will depend on the incidence
466 of the main outcome. If it is too low, an increase in the number of patients included will
467 be performed with the inclusion of more blocks of participants. In order to have a more
468 accurate dimension, the sample size calculation will be revised as soon as we reach
469 half of the initially planned sample size.

470 **Statistical analysis methodology**

471 The database will be analyzed using the SPSS software, version 22.0, and R software,
472 version 4.0.2. Descriptive analysis will be performed by charts and descriptive
473 statistics. The inferential analysis will consider a maximum significance level of 5%.
474 The chi-square test or Fisher's exact test will be used for inferential analysis of the
475 distributions of categorical variables. The odds ratio (OR) will be the measure used to
476 estimate risk. The OR's significance will be evaluated by the OR's asymptotic
477 confidence interval. The hypothesis of normality will be verified by the Kolmogorov–
478 Smirnov and Shapiro–Wilk tests. Student's t-test or Mann-Whitney test will be used in
479 the comparison of the two independent groups. More than two independent groups
480 will be compared by the ANOVA or by the Kruskal–Wallis test. Two repeated measures
481 in different assessments will be compared by the paired Student's t-test or by the

482 Wilcoxon's signed-rank test. More than two repeated measures will be compared by
483 the ANOVA for repeated measures, or by the Friedman's test.

484 The identification of an optimal cutoff point for the marker associated with an outcome
485 will be established through the analysis of the receiver operating characteristic (ROC)
486 curve. The performance will be evaluated by the area under the ROC curve (AUC),
487 and the significance of the AUC will be evaluated by the test that judges the null
488 hypothesis that AUC is equal to 0.5. In addition to the significance test, the asymptotic
489 confidence interval for the AUC will be obtained.

490 Analysis of the association between two quantitative variables will be visualized by
491 scatter plots and quantified by the Pearson correlation coefficient, in the case of normal
492 distributions, or by the Spearman's correlation coefficient, if normal distribution is not
493 verified in at least one of the variables. The significance of the correlation coefficient
494 will be evaluated by the correlation coefficient test.

495 Linear or non-linear regression models will be proposed to explain the relationship
496 between the clinical–radiological variables of the patient and the quantitative outcome
497 variables (colonization and multiomic profile). For the variable colonization (binary),
498 logistic regression models will be proposed. Regression model parameters will be
499 estimated by the maximum likelihood method, and the forward Wald method will be
500 used to choose the variables. The goodness of fit of the model will be analyzed by
501 adherence statistics, residual analysis, and verification of theoretical assumptions of
502 the model.

503 **Ethics and dissemination**

504 The protocol will follow the ethical standards of the HUGG REC. All patients whose
505 biological materials will be analyzed will be well-informed of the research objectives
506 and will sign ICF, agreeing with the availability of samples for further laboratory
507 analysis.

508 **Acknowledgements**

509 The authors gratefully acknowledge the Brazilian agencies Conselho Nacional de
510 Desenvolvimento Científico e Tecnológico (CNPq), Fundação Carlos Chagas Filho de
511 Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ) and the Coordenação de
512 Aperfeiçoamento de Pessoal de Nível Superior - Brasil (CAPES) - Finance Code 001
513 for supporting this study.

514 **Competing interests statement**

515 The researchers declare no conflicts of interest.

516

517 **Authors' contributions**

518 VMR: conception and design of the work, data collection, data analysis and
519 interpretation, and drafting the article. COGXL: conception and design of the work,
520 data collection. EOF: conception and design of the work, data collection, data analysis
521 and interpretation, critical revision of the article and final approval of the version to be
522 published. GCF: electronic data storage. FCSN: data analysis and interpretation.
523 LCMA: data analysis and interpretation. KMC: statistical design of the work, data
524 analysis and interpretation. RKAF: critical revision of the article and final approval of
525 the version to be published.

526

527

528

529

530

531

532

533

534

535

536

537 **References**

- 538 1. Modic MT, Masaryk TJ, Ross JS, Carter JR. Imaging of degenerative disk
539 disease. *Radiology* [Internet]. 1o de julho de 1988 [citado 25 de julho de 2021];
540 Disponível em: <https://pubs.rsna.org/doi/abs/10.1148/radiology.168.1.3289089>.
- 541 2. Modic MT, Steinberg PM, Ross JS, Masaryk TJ, Carter JR. Degenerative disk
542 disease: assessment of changes in vertebral body marrow with MR imaging.
543 *Radiology*. 1o de janeiro de 1988;166(1):193–9.
- 544 3. Tang G, Chen Y, Chen J, Wang Z, Jiang W. Higher proportion of low-virulence
545 anaerobic bacterial infection in young patients with intervertebral disc herniation. *Exp*
546 *Ther Med*. 2019/10/02 ed outubro de 2019;18(4):3085–9.
- 547 4. Capoor MN, Lochman J, McDowell A, Schmitz JE, Solansky M, Zapletalova M,
548 et al. Intervertebral disc penetration by antibiotics used prophylactically in spinal
549 surgery: implications for the current standards and treatment of disc infections. *Eur*
550 *Spine J*. 2018/12/07 ed abril de 2019;28(4):783–91.
- 551 5. Capoor MN, Ruzicka F, Machackova T, Jancalek R, Smrcka M, Schmitz JE, et
552 al. Prevalence of *Propionibacterium acnes* in Intervertebral Discs of Patients
553 Undergoing Lumbar Microdiscectomy: A Prospective Cross-Sectional Study. *PLoS*
554 *One*. 2016/08/19 ed 2016;11(8):e0161676.
- 555 6. Capoor MN, Konieczna A, McDowell A, Ruzicka F, Smrcka M, Jancalek R, et
556 al. Pro-Inflammatory and Neurotrophic Factor Responses of Cells Derived from
557 Degenerative Human Intervertebral Discs to the Opportunistic Pathogen
558 *Cutibacterium acnes*. *Int J Mol Sci* [Internet]. 2021/03/04 ed 26 de fevereiro de
559 2021;22(5). Disponível em: <https://www.ncbi.nlm.nih.gov/pubmed/33652921>
- 560 7. Capoor MN, Ruzicka F, Schmitz JE, James GA, Machackova T, Jancalek R, et
561 al. *Propionibacterium acnes* biofilm is present in intervertebral discs of patients
562 undergoing microdiscectomy. *PLoS One*. 2017/04/04 ed 2017;12(4):e0174518.
- 563 8. Schmid B, Hausmann O, Hitzl W, Achermann Y, Wuertz-Kozak K. The Role of
564 *Cutibacterium acnes* in Intervertebral Disc Inflammation. *Biomedicines* [Internet].
565 2020/07/08 ed 30 de junho de 2020;8(7). Disponível em:
566 <https://www.ncbi.nlm.nih.gov/pubmed/32629986>
- 567 9. Nguyen HP, Zaroff JG, Bayman EO, Gelb AW, Todd MM, Hindman BJ, et al.
568 Perioperative hypothermia (33 degrees C) does not increase the occurrence of
569 cardiovascular events in patients undergoing cerebral aneurysm surgery: findings from
570 the Intraoperative Hypothermia for Aneurysm Surgery Trial. *Anesthesiology*. agosto
571 de 2010;113(2):327–42.

- 572 10. Li B, Dong Z, Wu Y, Zeng J, Zheng Q, Xiao B, et al. Association Between
573 Lumbar Disc Degeneration and Propionibacterium acnes Infection: Clinical Research
574 and Preliminary Exploration of Animal Experiment. Spine Phila Pa 1976. 2015/12/15
575 ed 1o de julho de 2016;41(13):E764–9.
- 576 11. Yuan Y, Zhou Z, Jiao Y, Li C, Zheng Y, Lin Y, et al. Histological Identification
577 of Propionibacterium acnes in Nonpyogenic Degenerated Intervertebral Discs.
578 Biomed Res Int. 2017/04/13 ed 2017;2017:6192935.
- 579 12. Zheng Y, Lin Y, Chen Z, Jiao Y, Yuan Y, Li C, et al. Propionibacterium acnes
580 induces intervertebral discs degeneration by increasing MMP-1 and inhibiting TIMP-1
581 expression via the NF-kappaB pathway. Int J Clin Exp Pathol. 2018/07/01 ed
582 2018;11(7):3445–53.
- 583 13. Zhou Z, Chen Z, Zheng Y, Cao P, Liang Y, Zhang X, et al. Relationship between
584 annular tear and presence of Propionibacterium acnes in lumbar intervertebral disc.
585 Eur Spine J. 2015/08/20 ed novembro de 2015;24(11):2496–502.
- 586 14. Wang Y, Che M, Xin J, Zheng Z, Li J, Zhang S. The role of IL-1beta and TNF-
587 alpha in intervertebral disc degeneration. Biomed Pharmacother. 2020/08/28 ed
588 novembro de 2020;131:110660.
- 589 15. Albert HB, Sorensen JS, Christensen BS, Manniche C. Antibiotic treatment in
590 patients with chronic low back pain and vertebral bone edema (Modic type 1 changes):
591 a double-blind randomized clinical controlled trial of efficacy. Eur Spine J. abril de
592 2013;22(4):697–707.
- 593 16. Najafi S, Mahmoudi P, Bassampour SA, Shekarchi B, Soleimani M,
594 Mohammadimehr M. Molecular detection of Propionibacterium acnes in biopsy
595 samples of intervertebral disc with modic changes in patients undergoing herniated
596 disc surgery. Iran J Microbiol. dezembro de 2020;12(6):516–21.
- 597 17. Salehpour F, Aghazadeh J, Mirzaei F, Ziaei E, Alavi SAN. Propionibacterium
598 acnes Infection in Disc Material and Different Antibiotic Susceptibility in Patients With
599 Lumbar Disc Herniation. Int J Spine Surg. 2019/05/28 ed abril de 2019;13(2):146–52.
- 600 18. Arndt J, Charles YP, Koebel C, Bogorin I, Steib JP. Bacteriology of degenerated
601 lumbar intervertebral disks. J Spinal Disord Tech. 2012/07/27 ed outubro de
602 2012;25(7):E211-6.
- 603 19. Stirling A, Worthington T, Rafiq M, Lambert PA, Elliott TSJ. Association
604 between sciatica and Propionibacterium acnes. The Lancet. 2001;357(9273):2024–5.

- 605 20. Jiao Y, Lin Y, Zheng Y, Yuan Y, Chen Z, Cao P. The bacteria-positive proportion
606 in the disc tissue samples from surgery: a systematic review and meta-analysis. *Eur*
607 *Spine J.* 2019/07/18 ed dezembro de 2019;28(12):2941–50.
- 608 21. Rollason J, McDowell A, Albert HB, Barnard E, Worthington T, Hilton AC, et al.
609 Genotypic and antimicrobial characterisation of *Propionibacterium acnes* isolates from
610 surgically excised lumbar disc herniations. *Biomed Res Int.* 2013/09/26 ed
611 2013;2013:530382.
- 612 22. Carricajo A, Nuti C, Aubert E, Hatem O, Fonsale N, Mallaval FO, et al.
613 *Propionibacterium acnes* contamination in lumbar disc surgery. *J Hosp Infect.* julho de
614 2007;66(3):275–7.
- 615 23. Rigal J, Thelen T, Byrne F, Cogniet A, Boissiere L, Aunoble S, et al. Prospective
616 study using anterior approach did not show association between Modic 1 changes and
617 low grade infection in lumbar spine. *Eur Spine J.* 2016/01/29 ed abril de
618 2016;25(4):1000–5.
- 619 24. Urquhart DM, Zheng Y, Cheng AC, Rosenfeld JV, Chan P, Liew S, et al. Could
620 low grade bacterial infection contribute to low back pain? A systematic review. *BMC*
621 *Med.* 2015/01/23 ed 22 de janeiro de 2015;13:13.
- 622 25. Astur N, Martins DE, Wajchenberg M, Ferretti M, Menezes FG, Doi AM, et al.
623 Subclinical *Propionibacterium acnes* infection estimation in the intervertebral disc
624 (SPInE-ID): protocol for a prospective cohort. *BMJ Open.* 2017/11/21 ed 17 de
625 novembro de 2017;7(11):e017930.
- 626 26. Evangelopoulos DS, Stathopoulos IP, Morassi GP, Koufos S, Albarni A,
627 Karampinas PK, et al. Sonication: A Valuable Technique for Diagnosis and Treatment
628 of Periprosthetic Joint Infections. *Sci World J.* 10 de outubro de 2013;2013:e375140.
- 629 27. Suarez S, Nassif X, Ferroni A. [Applications of MALDI-TOF technology in
630 clinical microbiology]. *Pathol Biol (Paris).* fevereiro de 2015;63(1):43–52.
- 631 28. Barnard E, Nagy I, Hunyadkurti J, Patrick S, McDowell A. Multiplex touchdown
632 PCR for rapid typing of the opportunistic pathogen *Propionibacterium acnes*. *J Clin*
633 *Microbiol.* 2015/01/30 ed abril de 2015;53(4):1149–55.
- 634 29. Rajasekaran S, Tangavel C, Aiyer SN, Nayagam SM, Raveendran M, Demonte
635 NL, et al. ISSLS PRIZE IN CLINICAL SCIENCE 2017: Is infection the possible initiator
636 of disc disease? An insight from proteomic analysis. *Eur Spine J.* 2017/02/09 ed maio
637 de 2017;26(5):1384–400.

- 638 30. Rinschen MM, Ivanisevic J, Giera M, Siuzdak G. Identification of bioactive
639 metabolites using activity metabolomics. *Nat Rev Mol Cell Biol.* 2019/03/01 ed junho
640 de 2019;20(6):353–67.
- 641 31. Swank KR, Furness JE, Baker EA, Gehrke CK, Biebelhausen SP, Baker KC.
642 Metabolomic Profiling in the Characterization of Degenerative Bone and Joint
643 Diseases. *Metabolites* [Internet]. 2020/06/04 ed 29 de maio de 2020;10(6). Disponível
644 em: <https://www.ncbi.nlm.nih.gov/pubmed/32485832>
- 645 32. Ou J, Xiao M, Huang Y, Tu L, Chen Z, Cao S, et al. Serum Metabolomics
646 Signatures Associated With Ankylosing Spondylitis and TNF Inhibitor Therapy. *Front*
647 *Immunol.* 2021/03/09 ed 2021;12:630791.
- 648 33. Fernandez-Garcia M, Rojo D, Rey-Stolle F, Garcia A, Barbas C. Metabolomic-
649 Based Methods in Diagnosis and Monitoring Infection Progression. *Exp Suppl.*
650 2018/12/12 ed 2018;109:283–315.
- 651 34. Johnson CH, Ivanisevic J, Siuzdak G. Metabolomics: beyond biomarkers and
652 towards mechanisms. *Nat Rev Mol Cell Biol.* 2016/03/17 ed julho de 2016;17(7):451–
653 9.
- 654 35. Shan L, Yang J, Meng S, Ruan H, Zhou L, Ye F, et al. Urine Metabolomics
655 Profiling of Lumbar Disc Herniation and its Traditional Chinese Medicine Subtypes in
656 Patients Through Gas Chromatography Coupled With Mass Spectrometry. *Front Mol*
657 *Biosci.* 2021/06/29 ed 2021;8:648823.
- 658 36. Teckchandani S, Nagana Gowda GA, Raftery D, Curatolo M. Metabolomics in
659 chronic pain research. *Eur J Pain.* 2020/10/17 ed fevereiro de 2021;25(2):313–26.
- 660 37. Liu M, Xie Z, Costello CA, Zhang W, Chen L, Qi D, et al. Metabolomic analysis
661 coupled with extreme phenotype sampling identified that lysophosphatidylcholines are
662 associated with multisite musculoskeletal pain. *Pain.* 2020/08/25 ed 1o de fevereiro
663 de 2021;162(2):600–8.
- 664 38. Fujita N, Ishihara S, Michikawa T, Azuma K, Suzuki S, Tsuji O, et al. Potential
665 association of metabolic and musculoskeletal disorders with lumbar intervertebral disc
666 degeneration: Cross-sectional study using medical checkup data. *J Orthop Sci.*
667 2019/06/10 ed maio de 2020;25(3):384–8.
- 668 39. Aroke EN, Powell-Roach KL. The Metabolomics of Chronic Pain Conditions: A
669 Systematic Review. *Biol Res Nurs.* 2020/07/16 ed outubro de 2020;22(4):458–71.
- 670 40. Ji RR, Donnelly CR, Nedergaard M. Astrocytes in chronic pain and itch. *Nat*
671 *Rev Neurosci.* 2019/09/21 ed novembro de 2019;20(11):667–85.

- 672 41. Wu X, Xiang H, Zhang G, Hu Y, wang yan, Chen B. A metabolic profiling
673 analysis of degenerative intervertebral disc disease in a rabbit model via GC/TOF-MS.
674 2019; Disponível em: <https://www.researchsquare.com/article/rs-7971/v1>
- 675 42. Radek M, Pacholczyk-Sienicka B, Jankowski S, Albrecht L, Grodzka M, Depta
676 A, et al. Assessing the correlation between the degree of disc degeneration on the
677 Pfirrmann scale and the metabolites identified in HR-MAS NMR spectroscopy. *Magn*
678 *Reson Imaging*. 2015/12/29 ed maio de 2016;34(4):376–80.
- 679 43. Teraguchi M, Yoshimura N, Hashizume H, Muraki S, Yamada H, Oka H, et al.
680 Metabolic Syndrome Components Are Associated with Intervertebral Disc
681 Degeneration: The Wakayama Spine Study. *PLoS One*. 2016/02/04 ed
682 2016;11(2):e0147565.
- 683 44. Veras MA, Lim YJ, Kuljanin M, Lajoie GA, Urquhart BL, Seguin CA. Protocol
684 for parallel proteomic and metabolomic analysis of mouse intervertebral disc tissues.
685 *JOR Spine*. 2020/10/06 ed setembro de 2020;3(3):e1099.
- 686 45. Tang G, Han X, Lin Z, Qian H, Chen B, Zhou C, et al. *Propionibacterium acnes*
687 Accelerates Intervertebral Disc Degeneration by Inducing Pyroptosis of Nucleus
688 Pulposus Cells via the ROS-NLRP3 Pathway. *Oxid Med Cell Longev*. 2021/02/20 ed
689 2021;2021:4657014.
- 690 46. Lin Y, Jiao Y, Yuan Y, Zhou Z, Zheng Y, Xiao J, et al. *Propionibacterium acnes*
691 induces intervertebral disc degeneration by promoting nucleus pulposus cell apoptosis
692 via the TLR2/JNK/mitochondrial-mediated pathway. *Emerg Microbes Infect*.
693 2018/01/13 ed 10 de janeiro de 2018;7(1):1.
- 694 47. Capoor MN, Ruzicka F, Sandhu G, Rollason J, Mavrommatis K, Ahmed FS, et
695 al. Importance of *Propionibacterium acnes* hemolytic activity in human intervertebral
696 discs: A microbiological study. *PLoS One*. 2018/11/30 ed 2018;13(11):e0208144.
- 697 48. Albert HB, Kjaer P, Jensen TS, Sorensen JS, Bendix T, Manniche C. Modic
698 changes, possible causes and relation to low back pain. *Med Hypotheses*.
699 2008;70(2):361–8.
- 700 49. Ohtori S, Koshi T, Yamashita M, Yamauchi K, Inoue G, Suzuki M, et al.
701 Existence of pyogenic spondylitis in Modic type 1 change without other signs of
702 infection: 2-year follow-up. *Eur Spine J*. 2010/03/10 ed julho de 2010;19(7):1200–5.
- 703 50. Ritter PL, González VM, Laurent DD, Lorig KR. Measurement of pain using the
704 visual numeric scale. *J Rheumatol*. março de 2006;33(3):574–80.

- 705 51. Breivik H, Borchgrevink PC, Allen SM, Rosseland LA, Romundstad L, Hals
706 EKB, et al. Assessment of pain. *Br J Anaesth*. julho de 2008;101(1):17–24.
- 707 52. Bagattini ÂM, Camey SA, Miguel SR, Andrade MV, de Souza Noronha KVM,
708 de C. Teixeira MA, et al. Electronic Version of the EQ-5D Quality-of-Life
709 Questionnaire: Adaptation to a Brazilian Population Sample. *Value Health Reg Issues*.
710 1o de dezembro de 2018;17:88–93.
- 711 53. Vigatto R, Alexandre NM, Correa Filho HR. Development of a Brazilian
712 Portuguese version of the Oswestry Disability Index: cross-cultural adaptation,
713 reliability, and validity. *Spine Phila Pa 1976*. 2007/02/17 ed 15 de fevereiro de
714 2007;32(4):481–6.
- 715 54. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina
716 sequence data. *Bioinforma Oxf Engl*. 1o de agosto de 2014;30(15):2114–20.
- 717 55. Lohse M, Bolger AM, Nagel A, Fernie AR, Lunn JE, Stitt M, et al. RobiNA: a
718 user-friendly, integrated software solution for RNA-Seq-based transcriptomics.
719 *Nucleic Acids Res*. julho de 2012;40 (Web Server issue):W622-627.
- 720 56. Shah H, Encheva V, Schmid O, Culak RA, Nasir P, Ines I, et al. Surface
721 Enhanced Laser Desorption/Ionization Time of Flight Mass Spectrometry (SELDI-
722 TOF-MS): A Potentially Powerful Tool for Rapid Characterisation of Microorganisms.
723 In 2005. p. 57–95.
- 724 57. Heberle H, Meirelles GV, da Silva FR, Telles GP, Minghim R. InteractiVenn: a
725 web-based tool for the analysis of sets through Venn diagrams. *BMC Bioinformatics*.
726 22 de maio de 2015;16(1):169.
- 727 58. Urrutia J, Besa P, Campos M, Cikutovic P, Cabezon M, Molina M, et al. The
728 Pfirrmann classification of lumbar intervertebral disc degeneration: an independent
729 inter- and intra-observer agreement assessment. *Eur Spine J*. 2016/02/18 ed
730 setembro de 2016;25(9):2728–33.
- 731 59. Medronho R, Bloch K, Luiz R, Werneck G. *Epidemiologia. Atheneu. São Paulo*.
732 2009;

733

	STUDY PERIOD							
	Enrolment	Allocation	Post-allocation					Close-out
	Aug/22	Set/22	Oct/22	Dec/22	Feb/23	Apr/23	Jun/23	Aug/23
ENROLMENT:								
Eligibility screening	X		X					
Informed consent			X					
Clinical Survey			X					
Images Evaluation			X					
Allocation		X						
INTERVENTIONS:								
Surgery			←————→					
Sampling			←————→					
Sample Analysis			←————→					
ASSESSMENTS:								
List baseline variables	X	X						
Data processing				←————→				
Publication preparation								X

medRxiv preprint doi: <https://doi.org/10.1101/2022.07.08.22277406>; this version posted July 9, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

*Recommended content can be displayed using various schematic formats. See SPIRIT 2013 Explanation and Elaboration for examples from protocols.

**List specific timepoints in this row.

Fig 1




Fig 2